[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.248.103. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Invited Commentary
Diabetes and Endocrinology
September 28, 2018

Evaluating Artificial Intelligence Applications in Clinical Settings

Author Affiliations
  • 1Institute for Health Metrics and Evaluation, University of Washington, Seattle
JAMA Netw Open. 2018;1(5):e182658. doi:10.1001/jamanetworkopen.2018.2658

Artificial intelligence (AI)–based systems have been shown to reliably recognize cardiovascular disease risk1 and diagnose conditions such as diabetic retinopathy2,3 and melanoma4 from medical images. These advances in image-based medical diagnosis have been widely publicized in the media and similar tools have been approved by the US Food and Drug Administration (FDA). In April of 2018, the FDA approved the first AI device to provide screening decision for a disease (ie, diabetic retinopathy) without assisted interpretation by a clinician.5 Kanagasingam et al6 evaluated a similar approach—a convolutional neural network algorithm, a deep learning method—for identifying diabetic retinopathy from medical images in a primary care setting in Midland, Western Australia. Their system correctly classified the 2 severe cases captured in the data (193 patients with diabetes), and misclassified 15 (false-positives) individuals as having diabetic retinopathy. The number of patients needing to be reviewed by an ophthalmologist was less than 10%. These findings demonstrate the potential for these systems to support efficient and improved care, while also highlighting the need for rigorous evaluation in clinical settings.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×